Lupin Challenges Oscient’s Cholesterol Drug Patent

Law360 (December 3, 2008, 12:00 AM EST) -- Mumbai, India-based Lupin Ltd. is seeking to gain regulatory approval of a generic version of Oscient Pharmaceuticals Corp.’s drug Antara and is claiming a patent covering the treatment for high cholesterol is invalid and will not be infringed by the copycat version, according to Oscient.

Oscient, based in Waltham, Mass., said Wednesday it received notice that Lupin filed an abbreviated new drug application with the U.S. Food and Drug Administration to bring an Antara generic to market and said it has 45 days to decide whether...
To view the full article, register now.